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The circadian clock is required for the rhythmic expression of a plethora of genes that orchestrate me-
tabolism, sleep-wake behaviour and the immune response to pathogens. The cold-inducible RNA binding
protein (CIRBP) is required for high amplitude expression of clock genes. Moreover, CIRBP protects the
expression of clock genes from the inhibitory effects of tumour necrosis factor (TNF). However, since TNF
represses Cirbp expression, the protective effect of CIRBP is lost. Here, we show that the TNF effect on
Cirbp requires the non-canonical NF-κB signalling pathway. While a knock down of RelA does not alter
the effects of TNF on Cirbp, a knock down of RelB represses this effect. In addition, the data indicate that
p50 and p52 are required in the TNF induced inhibition of Cirbp. These results show that Cirbp expression
in TNF treated cells is regulated via the non-canonical NF-κB pathway.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Circadian rhythms are mediated by clock genes, and thereby
regulate metabolism and sleep-wake behaviour [1,2]. The main
transcription factors coordinating the circadian rhythms are
CLOCK and BMAL1, which form heterodimers and activate the
gene expression of Period (Per), Cryptochrome (Cry) and of various
clock controlled genes by binding to E-box motives [3]. Besides,
CLOCK can be substitute by its paralog NPAS2 [4]. The binding of
CLOCK:BMAL1 to the E-box is regulated by positive and negative
feedback mechanisms [3].
Recent studies point to a crosstalk between the clock and the
immune system. In mice it is well established that the response to
various pathogens and to pro-inﬂammatory cytokines is under
circadian control. Hence, the immune system of mice is especially
sensitive to pathogens at the beginning of their active phase [5].
The macrophage response to lipopolysaccharide (LPS) is decreased
in mice with an inactive clock gene [6]. The extent of secretion of
tumour necrosis factor (TNF) and interleukin (IL) -6 by LPS sti-
mulated macrophages follows a circadian rhythm [7]. A defect in
Per2 expression affects Toll-like receptor (TLR) 9 expression and
thus the vaccine response, when using TLR9 ligands as adjuvants
[8]. Besides of effects of the circadian system on the immune re-
sponse, the immune system also inﬂuences the circadian clock.
TNF inhibits the expression of all three Period genes and of ther B.V. This is an open access article
ontana).PAR-bZip transcription factors, Dbp, Tef and Hlf [9]. At least part of
these effects, are due to an interference with the E-box dependent
transcription [9]. Additionally, transforming growth factor beta
(TGFβ) has been shown to reduce the expression of several clock
genes, including Per1, Per3, Dbp and Tef [10,11]. The effect of TGFβ
is mediated by induction of Dec1 [11].
A recent study demonstrated that the cold-inducible RNA
binding protein (CIRBP, also called CIRP and hnRNP A18) interacts
with transcripts associated in circadian behaviour and that CIRBP
is required for high amplitude expression of clock genes [12].
CIRBP was originally identiﬁed as the ﬁrst mammalian cold shock
protein [13] and has been shown to be upregulated by various
cellular stresses, including hypoxia and UV-irradiation [14–16].
CIRBP belongs to the glycine rich RNA binding protein family and
is thought to modulate gene expression by stabilising transcripts
through binding to the 5′- untranslated region (UTR) or 3′- UTR
[12,17,18]. CIRBP is released by necrotic cells and thereby is found
in the serum of patients with hemorrhagic shock and sepsis [19].
By binding to TLR4, CIRBP activates the inﬂammasome and pro-
motes the production of proinﬂammatory cytokines, including TNF
and IL-6 [19]. Moreover, CIRBP has been reported to link in-
ﬂammation and tumorigenesis in colitis-associated cancer and to
increase reactive oxygen species (ROS) accumulation and CD133,
thereby leading to enhanced liver tumorigenesis [20,21].
Recently, we have demonstrated that TNF not only interferes
with E-box mediated expression of clock genes, but also impairs
the expression of Cirbp in ﬁbroblasts and neuronal cells [22]. The
inhibitory effect of TNF on clock genes is more pronounced inunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Inhibition of IKKα and IKKβ prevents TNF mediated inhibition of Cirbp ex-
pression. (A) NIH3T3 cells were treated with the IKKα and β inhibitors IKK III and
IKK VII in the presence or absence of TNF (10 ng/ml). Data show the expression of
Cirbp mRNA (A) and protein (B). As a control for the effectiveness of the NF-κB
blockers the expression of IκB was used, Data of RT-qPCR assays show the mean
þ/ SEM (error bars) of biological triplicates from three independent experiments.
Signiﬁcance of grouped results were calculated with one way-ANOVA and Bon-
nnn
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protects clock genes from the TNF effect [22]. These data indicate
that CIRBP counteracts the inhibitory effect of TNF on clock gene
expression. In the light of the role of TNF to exert many of its ef-
fects by activating the NF-κB pathway, we have analysed the in-
volvement of this signalling pathway in the TNF mediated in-
hibition of Cirbp expression.
In mammals, the NF-κB family comprises ﬁve different sub-
units, belonging to the Rel family, which can either hetero- or
homodimerise in order to form transcriptionally active isoforms.
These isoforms can have very different roles in the transcriptional
activation or repression of inﬂammatory genes [23]. The signalling
pathways that mediate NF-κB activation can be classiﬁed into
canonical and non-canonical (or alternative) pathways. In the ca-
nonical pathway, RelA (also known as p65) and p50 form het-
erodimers in order to activate gene expression. In a non-active
form this complex is bound to the inhibitory protein IκB which
keeps the heterodimer in the cytoplasm. Once IκB undergoes
phosphorylation and subsequently degradation the activated p65::
p50 complex translocates into the nucleus, binds to its consensus
sequences and activates the gene expression of its target genes
[24]. The activation of the non-canonical NF-κB pathway involves
different signalling molecules and leads to the predominant acti-
vation of the p52::RelB dimer [25]. RelB itself is very labile and
requires the initial binding of p100 [26], the precursor protein of
p52. Processing of p100 generates p52 and leads to the translo-
cation of the p52::RelB dimer into the nucleus [25,27].Although
p100 preferentially binds RelB, RelB can also form heterodimers
with p50 after IκB degradation. This complex is also able to
translocate into the nucleus but this pathway is less understood
[28].
Here, we show that inhibition of the NF-κB signalling prevents
from the TNF mediated suppression of Cirbp expression. Our data
point to the involvement of the non-canonical pathway in the TNF
effect on Cirbp.ferroni post-hoc test; po0.001. Western blots were quantitated by densito-
metric analysis; the respective data are given above the western blots.2. Material and methods
2.1. Treatment of cells with TNF and NF-κB inhibitors
NIH3T3 ﬁbroblasts (DSMZ), were grown in DMEM high glucose
(4,5 g/l) medium (Gibco) supplemented with 10% FCS (PAN Bio-
tech) and gentamicin (1x; Gibco). Cells were kept at 37 °C and 5%
CO2. For RT-qPCR analysis, cells were seed in triplicates in 12-well
plates in a density of 1105 per well. For Western Blots cells were
seed in T25 ﬂasks in a density of 1106 per ﬂask. Two days after
seeding, cells were synchronized by serum deprivation (1% FCS).
Whereas the NF-κB inhibitors IKK III (Calbiochem 401480) and IKK
VII (Calbiochem 401486) were added immediately after serum
deprivation, TNF (10ng/ml) (Peprotech) was added one hour later.
The concentrations we used for the blockers of the NF-κB signal-
ling pathway have already been described to be effective [29,30].
Isolation of RNA and protein was performed in cells cultured for
4 and 6 h respectively. The effect of the inhibitors was assessed in
cultures treated for 3 h in the presence or absence of TNF.
2.2. Treatment of cells with siRNA against p50, p52, RelB and RelA
NIH3T3 cells and primary ﬁbroblasts were seeded in 6-well plates
(1.5105). After 24 h they were transfected with DharmaFECT
1 transfection reagent (Dharmacon) and 25 nM of siRNA (Dharma-
con) against p50, p52 or RelB. Gapdh and no target siRNA were used
as positive and negative controls, respectively. The siRNA targeting
RelA was obtained from QIAGEN. After transfection cells were in-
cubated for 36 h for RNA analysis and 48 h for protein analysis.2.3. RNA isolation and gene expression analysis
Whole-cell RNA from cultured cells was extracted using Nu-
cleoSpin-RNA II kit RNA (Machery Nagel) according to protocol.
Subsequently, 1 mg RNA was reverse-transcribed using random
hexamers (Fermentas) and M-MuLV reverse transcriptase (Life
Technologies). 20 ng of cDNA was ampliﬁed in a CFX384 detection
system (Biorad) using the TaqMan precision PLUS Master mix
(Primerdesign). The gene expression level was normalised to three
housekeeping genes (eEF1a1, HPRT, GAPDH) using qBase software
[31]. Each CT value used for these calculations is the mean of
duplicates of the same reaction. Relative RNA levels are expressed
as percentages of the average control groups. Taqman primers
were obtained from Primerdesign and Life Technologies.
2.4. Analysis of CIRBP by Western Blot
Cells were lysed with the IP lysis buffer (Pierce) as described in
the protocol. Whole protein extracts (50 mg) in LDS sample buffer
(Invitrogen) and DTT were applied on a NuPAGE 12% Bis-Tris-Gel
(Invitrogen). The proteins were separated at constant 150 V in a
MES SDS running buffer (Invitrogen). Subsequently, blotting on a
PVDF membrane was performed in a full wet tank blot at 30 V.
Membranes were incubated with a CIRBP rabbit polyclonal anti-
body recognising the C terminus of mouse CIRBP [32]. As sec-
ondary antibody an HRP-conjugated goat anti-rabbit (ab79051,
Abcam) was used. As a loading control, an antibody to the mouse
nuclear matrix protein p84 was used (ab487); with a goat to
Fig. 2. Knockdown of RelB, but not of RelA prevents from the inhibitory effect of TNF on Cirbp expression. Cells transfected with siRNA against RelA (A and C) or siRNA
against RelB (B and D) were left untreated or treated with TNF (10 ng/ml) for 4 h. Data show the expression of Cirbp (A and B) and the effectiveness of siRNA treatment
against RelA (C) and RelB (D). Knockdown reduces RelA expression by 77% and RelB by 70%. Data of RT-qPCR assays show the mean þ/SEM (error bars) of biological
triplicates from three independent experiments. Signiﬁcance of grouped results were calculated with one way-ANOVA and Bonferroni post-hoc test; signiﬁcance for siRNA
effectivity was calculated with a two-tailed Student's t-test; n po0.01 nnn po0.001.
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(ab7917) was from Abcam and the IκB antibody (9242) from Cell
Signaling Technology. Densitometric analysis was done using Im-
ageJ software. The protein marker used was the prestained protein
ladder V (PL005) from Geneaid.
2.5. Statistics
All experiments were performed in biological triplets and
analysed with GraphPad Prism (GraphPad Software). To assess the
statistical signiﬁcance between single series of measurements we
used the two-tailed Student’s t-test. For grouped measurements
with one variable for the selected genes, a one-way ANOVA was
used, followed by a Bonferroni post-hoc test to decrease the
likelihood of a rare event in multiple comparisons. P values less
than 0.05 were considered signiﬁcant, 0.01 in ANOVAs with post-
hoc tests. Data are shown as mean þ/ SEM of triplicate cultures.3. Results
3.1. Inhibition of NF-κB signalling pathway interferes with TNF
mediated suppression of Cirbp expression
We have recently reported that treatment of NIH3T3 cells with
TNF reduces the expression of Cirbp [22]. To assess the involve-
ment of the NF-κB pathway we blocked this pathway by using IKK
III and IKK VII, the compounds being well described to interferewith the effects of IKKα and IKKβ, respectively [30,33]. As shown
in Fig. 1A TNF inhibits the expression of Cirbp by 29%. Treatment
with IKK III (1 mM) reduced the extent of inhibition to 10%. The
increase of IKK III concentrations to 4 mM enhanced basal ex-
pression of Cirbp and blocked the inhibitory effect of TNF. IKK VII
in concentrations of 100 nM was sufﬁcient to prevent any sig-
niﬁcant inhibitory effect of TNF on Cirbp. As described recently the
effect of TNF on Cirbp expression is also seen at the protein level
(Fig. 1B) [22]. When adding IKK III (1 mM) the extent of TNF in-
duced inhibition was reduced. Unlike the basal expression of Cirbp
mRNA the expression of CIRBP protein was not enhanced when
adding IKK III at higher concentrations (4 mM). Still, also at this
concentration IKK III interfered with TNF mediated inhibition of
CIRBP. The effects of IKK VII resembled those seen with the higher
concentrations of IKK III, namely inhibition of basal expression of
CIRBP and prevention of the inhibitory effect of TNF (Fig. 1B). To
assess the effectiveness of IKK III and IKK VII we used IκB as a
positive control. Whereas higher concentrations of IKK III effec-
tively prevented from the suppression of the TNF mediated in-
hibition of IκB, IKK VII was less effective.
3.2. Regulation of Cirbp expression via the non-canonical NF-κB
signalling pathway
In the light of the well described effect of TNF to activate the
canonical NF-κB signalling pathway we knocked down RelA ex-
pression in NIH3T3 cells using siRNA. Surprisingly, the down-
regulation of RelA did not protect the cells from TNF mediated
Fig. 3. Knockdown of p50 and p52 reduces the TNF induced inhibition of Cirbp
expression. NIH3T3 cells were transfected with siRNA against p50, p52 or both.
Thereafter, cells were treated with TNF (10 ng/ml). Expression of mRNA (Fig. 3A)
and protein (Fig. 3B) was assessed after 4 h and 6 h of TNF treatment, respectively.
Compared to nontransfected control cells knockdown of p52 reduces Cirbp mRNA
expression by 42%. Densitometric analysis shows data for CIRBP and p50. Since the
antibodies to p52 proved not to work reliably, the respective data are not included.
Data of RT-qPCR assays show the mean þ/ SEM (error bars) of biological tripli-
cates from four independent experiments. Signiﬁcance of grouped results were
calculated with one way-ANOVA and Bonferroni post-hoc test; nn po0.01, nnn
po0.001; n without line signiﬁcance compared to untreated NIH3T3; # gives sig-
niﬁcance compared to NIH3T3þTNF.
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targeting RelB to analyse whether the TNF effect on Cirbp might
require the non-canonical NF-κB signalling pathway. A knock
down of RelB in NIH3T3 cells reduced basal expression of Cirbp and
prevented from the inhibitory effect of TNF on Cirbp (Fig. 2B). Ef-
fectiveness of siRNA treatment was assessed by controlling the
expression of RelA and RelB in transfected cells (Figs. 2C and D).
Taken collectively, the data indicate that the TNF effect on Cirbp
involves the non-canonical NF-κB signalling pathway.
3.3. Knock down of p50 or p52 seem to inhibit the TNF effect on
Cirbp
Since the knock down of RelB reduces the inhibitory effect of
TNF on Cirbp expression, we assessed the involvement of RelB’s
binding partners in the TNF effect observed. RelB preferentially
binds to p100/p52, but also forms heterodimers with p50 [28]. As
shown in Fig. 3A, TNF failed to reduce the expression of Cirbp in
NIH3T3 cells transfected with siRNA against p50 or against p52.
Analogously, the knockdown of both genes mimicked the afore-
mentioned effects. Effectiveness of siRNA treatment was again
assessed by controlling the expression of p50 and p52 in trans-
fected cells (Fig S1). Western blots show the knockdown of p50
and of p52 to reduce the basal expression of CIRBP, an effect not
being seen in NIH3T3 cells transfected with siRNA against bothgenes (Fig. 3B). The inhibitory effect of TNF was not observed in
cells transfected with siRNA against p50 or against both p50 and
p52. A single knockdown of p52 was less effective.4. Discussion
The data presented here shows that the NF-κB signalling
pathway plays a pivotal role in the previously described effect of
TNF to inhibit the expression of Cirbp [22]. In a ﬁrst approach, we
used the NF-κB inhibitors IKK III and IKK VII, which both have
been well described to interfere with NF-κB activation. IKK III has
been described to block cytokine production, to interfere with TNF
mediated expression of adhesions receptors in endothelial cells
and supress the immune response. IKK VII has been described as a
potent IKKβ inhibitor being even effective in low-nanomolar range
[29,30,34]. Both inhibitors effectively blocked the inhibitory effect
of TNF on Cirbp expression. When exploring the involvement of
individual components required for NF-κB activation by using
siRNAs, we identiﬁed RelB, rather than RelA to be essential for TNF
mediated inhibition of Cirbp. Thus, TNF effects on Cirbp are
mediated via the non-canonical pathway. This is especially inter-
esting since TNF is known to activate the canonical NF-κB pathway
rather than the non-canonical one. This has been worked out in
different biological systems. For example, mice lacking RelA loose
the protection from TNF induced apoptosis [35]. The TNF mediated
induction of the leukaemia inhibitory factor (LIF) is abolished in
relA knock out cells [36]. In contrast, RelB has been described to
repress Tnf mRNA expression by epigenetic silencing the promotor
[37]. Further, TNF has been shown to induce p100, which in return
inhibits RelB::p50 complexes [38]. Since RelB forms heterodimers
we assessed the role of its main binding partner p52. Indeed,
siRNA against p52 were effective in prevention of inhibitory TNF
effects on Cirbp. TNF stimulation has been described to induce a
delayed processing of p100 to form p52 thereby leading to a
postponed activation of the non-canonical NF-κB pathway [39].
On the other hand, we ﬁnd that besides of the contribution of RelB
and p52, also p50 to be essential in the TNF effects studied. A
knock down of p50, which forms heterodimers with RelA, leads
also to an inhibition of the TNF effect on Cirbp. However, p50 can
also form heterodimers with RelB. This complex is also able to
induce gene expression [28]. Besides, p50 homodimers are known
to block the expression of Tnf mRNA [40].
CIRBP has been shown to be required for high amplitude ex-
pression of clock genes [12]. Further, the TNF dependent down-
regulation of clock genes has been shown to be dependent on
Cirbp expression [22]. However, the downregulation of Cirbp only
plays a role in inhibition of clock gene expression when adding
TNF at low doses (1 ng/ml). When using higher TNF concentrations
downregulation of clock genes was found to depend on TNF in-
duced induction of Twist1 [41]. Twist1 was found to interfere with
CLOCK mediated activation of E-boxes in the promoter regions of
clock genes. In the light of the data on TNF effects on Cirbp ex-
pression to depend on NF-κB activation, it is interesting that also
the upregulation of Twist1 by TNF is mediated through NF-κB
signalling [42,43]. Hence, the NF-κB signalling pathway might be
the main regulator of clock gene expression in inﬂammation.
In conclusion, we showed that TNF mediated downregulation
of Cirbp requires several components of the NF-κB signalling
pathway, namely RelB, p50 and p52, while RelA seems not to be
required for this effect. Thus, this process appears to be regulated
through the non-canonical NF-κB pathway.
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